Currently Viewing:
AMCP 2017
Currently Reading
Dr Jennifer Graff on How Payers Make Decisions
August 01, 2017
Dr Jacqueline Glover: Financial Knowledge Is Part of Informed Consent
July 10, 2017
Laura Topor Explains the Value of Real-Time Benefit Transactions
June 27, 2017
Dr Jacqueline Glover: Clinicians' Obligations of Justice Regarding Costs of Care
June 24, 2017
Dr Lou Garrison Discusses Challenges of Working With Real-World Data
June 16, 2017
Dr Neil Minkoff Explains How 340B Impacts Pharmacies and Payers Differently
June 15, 2017
Dr Matthew Pickering on Working With Health Plans on Measure Implementation
June 09, 2017
Laura Topor: Clearing Up Misconceptions About e-Prescribing
June 07, 2017
Dr Jacqueline Glover Discusses the Complicated Balance of Ethics in Drug Trials
June 05, 2017
Dr Richard J. Willke Discusses Challenges of Working With Real-World Data
June 02, 2017
Susan A. Cantrell Explains the Necessity of Pre- and Post-Approval Communications
May 31, 2017
Dr Neil Minkoff Discusses Evolution and Consequences of 340B Programs
May 30, 2017
Dr Doug Hillblom Discusses Legislative Pushes Toward e-Prescribing
May 25, 2017
Dr Matthew Pickering Describes Challenges of New Measure Implementation
May 24, 2017
Dr Aimee Tharaldson Discusses the Orphan Drug Approval Trend
May 22, 2017
Dr Gail Bridges on the Importance of Real-World Results Matching Clinical Trial Outcomes
May 21, 2017
Dr Liz Zhou Discusses Real-World Implications of Toujeo Switching Trial
May 19, 2017
Dr Richard J. Willke on the Value of Real-World Data for Health Plans
May 18, 2017
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Analyzing the Near-Term Pipeline for Specialty Drugs

Laura Joszt
The Academy of Managed Care Pharmacy Annual Meeting kicked off on March 28, 2017, in Denver, Colorado, with a look at the specialty pharmaceutical pipeline with Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.
Multiple Sclerosis
The current treatments for multiple sclerosis (MS) include immunomodulators, monoclonal antibodies, and oral therapies. However, these has been significant development for patients with progressive MS, for which there are currently no FDA-approved treatment options.
 
There are 6 drugs in development for progressive MS. About 15% of patients are diagnosed with primary progressive MS, for which there are no acute relapses or remission.
 
Ocrelizumab was is expected to be approved on March 28, although it hadn’t been approved yet when Tharaldson spoke. The drug treats primary progressive MS and can treat relapsing forms; however, she noted some safety concerns that need to be monitored, such as the fact that 2.3% of patients developed tumors.
 
Cancer
There are a large number of cancer drugs even in the near-term pipeline. Current treatments for cancer include chemotherapy, targeted therapies, and immunotherapies. Tharaldson expects to see more breakthrough therapies approved, which will bring more treatments to the market more quickly, as well as more targeted therapies.
 
She noted a list of 22 drugs in the near-term pipeline, which didn’t even cover all the drugs in the near-term pipeline. Already, 11 are pending approval. Among the drugs being watched is midostaurin, which would treat acute myeloid leukemia (AML) and systemic mastocytosis. This is a breakthrough therapy for AML as these specific patients do not have a treatment, Tharaldson said.
 
In addition, the first CAR-T treatment, tisagenlecleucel-T for acute lymphocytic leukemia, is expected to be approved in October 2017.
 
“These CAR-Ts are interesting, you have to keep an eye on these medications,” Tharaldson said. “They’re very effective in clinical trials.”
 
CAR-T treatments are immunotherapies that are sent to a manufacturer to develop the antibodies to be infused in patients. It is a 3-week process and given as 1 infusion. However, they can cause cytokine release syndrome and neurotoxicity has also been seen in clinical trials.
 
“But, again, they’re very effective for patients who have no other treatment options,” she said.
 
NASH
While there aren’t any drugs in the near-term pipeline for nonalcoholic steatohepatitis (NASH), Tharaldson spent the time to go through some drugs in development because this is poised to be a very expensive drug class.
 
NASH is when there is fat in the liver, plus liver inflammation, plus liver damage, diagnosed by liver biopsy. As many as 16 million Americans have NASH, and another 6 to 10 million are at high risk of developing it. NASH is associated with comorbidities such as high cholesterol, type 2 diabetes, insulin resistance, and obesity.
 
“There really are limited treatment options other than losing weight eating a healthy diet, exercise and then obviously treating the comorbidities as well,” she said.
 
The soonest a drug may be available to treat NASH is 2019, and many of the drugs in development are oral therapies. However, Tharaldson noted that semaglutide, which is expected to be approved in September for diabetes, is also being looked at for NASH.
 
“It is expected that the NASH market could be as much as $35 billion per year,” she said. “So there’s a lot of focus on NASH.”


 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!